inzomelid
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 16, 2019 (NCT04015076)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
NLRP3 activator
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)n1ccc(S(=O)(=O)NC(=O)Nc2c3c(cc4c2CCC4)CCC3)n1- Mol. weight
- 388.49 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650350 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04338997 | Phase 1 | May 31, 2020 | Inflazome, University of Groningen |
| NCT04015076 | Phase 1 | Jul 16, 2019 | Inflazome, Nucleus Network Ltd |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Inflazome | For profit | 2 | 2 | 1 | 2019 |
| Nucleus Network Ltd | For profit | 1 | 0 | 1 | 2019 |
| University of Groningen | Academic/Hospital | 1 | 0 | 1 | 2020 |
3 organizations
Page 1 / 1